Inventor · disambiguated record
Jacqulyne Robichaux
Also filed as: ROBICHAUX JACQULYNE · ROBICHAUX JACQULYNE P
2 granted patents·16 pending applications·2 citations·filing 2017–2025
37Inventor score
Files withUNIV TEXAS18
Top patents by PatentIndex Score
18 records- 0176US11446302B2Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutationsUNIV TEXAS·Filed 2017·Granted Sep 20, 2022·2 cites·18 claims
- 0259US2023233563A1Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 mutationsUNIV TEXAS·Filed 2022·Application pending·0 cites
- 0357US2025312348A1Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertionsUNIV TEXAS·Filed 2025·Application pending·0 cites
- 0452US2024374597A1Methods and compositions for treatment of kras mutant cancerUNIV TEXAS·Filed 2022·Application pending·0 cites
- 0550US2024108623A1Methods of treating cancer with poziotinibUNIV TEXAS·Filed 2022·Application pending·0 cites
- 0649US11365189B2Heterocyclic inhibitors of tyrosine kinaseUNIV TEXAS·Filed 2020·Granted Jun 21, 2022·0 cites·30 claims
- 0749US2022143023A1Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertionsUNIV TEXAS·Filed 2020·Application pending·0 cites
- 0848US2024384350A1Methods of treating cancer with kinase inhibitorsUNIV TEXAS·Filed 2022·Application pending·0 cites
- 0946US2022194940A1Heterocyclic inhibitors of tyrosine kinaseUNIV TEXAS·Filed 2020·Application pending·0 cites
- 1045US2023121116A1Use of quinazoline-based tyrosine kinase inhibitors for the treatment of cancers with nrg1 fusionsUNIV TEXAS·Filed 2021·Application pending·0 cites
- 1145US2023112470A1Use of egfr/her2 tyrosine kinase inhibitors and/or her2/her3 antibodies for the treatment of cancers with nrg1 fusionsUNIV TEXAS·Filed 2021·Application pending·0 cites
- 1245US2023069749A1Use of poziotinib for the treatment of cancers with nrg1 fusionsUNIV TEXAS·Filed 2021·Application pending·0 cites
- 1345US2022041751A1Combination therapy for the treatment of cancerUNIV TEXAS·Filed 2019·Application pending·0 cites
- 1443US2022193074A1Compounds with anti-tumor activity against cancer cells bearing tyrosine kinase inhibitor resistant egfr mutationsUNIV TEXAS·Filed 2020·Application pending·0 cites
- 1542US2022175778A1Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertionsUNIV TEXAS·Filed 2020·Application pending·0 cites
- 1642US2021361655A1Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutationsUNIV TEXAS·Filed 2019·Application pending·0 cites
- 1741US2022175779A1Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutationsUNIV TEXAS·Filed 2020·Application pending·0 cites
- 1841US2021015819A1Methods for treatment of cancers with egfr activating mutationsUNIV TEXAS·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jacqulyne Robichaux files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →